

1 **Discovery and biosynthesis of the antibiotic bicyclomycin in distant bacterial**  
2 **classes**

3

4 Natalia M. Vior,<sup>a</sup> Rodney Lacret,<sup>a</sup> Govind Chandra,<sup>a</sup> Siobhán Dorai-Raj,<sup>a</sup> Martin Trick,<sup>b</sup> Andrew W.  
5 Truman<sup>a#</sup>

6

7 <sup>a</sup> Department of Molecular Microbiology, John Innes Centre, Norwich, UK

8 <sup>b</sup> Department of Computational and Systems Biology, John Innes Centre, Norwich, UK

9

10 **Running title:** Bicyclomycin biosynthesis and phylogeny

11

12 <sup>#</sup> Address correspondence to Andrew W. Truman, [andrew.truman@jic.ac.uk](mailto:andrew.truman@jic.ac.uk)

13

14

15

16

17

18

## 19 **ABSTRACT**

20 Bicyclomycin (BCM) is a clinically promising antibiotic that is biosynthesised by *Streptomyces*  
21 *cinnamoneus* DSM 41675. BCM is structurally characterized by a core cyclo(L-Ile-L-Leu) 2,5-  
22 diketopiperazine (DKP) that is extensively oxidized. Here, we identify the BCM biosynthetic gene  
23 cluster, which shows that the core of BCM is biosynthesised by a cyclodipeptide synthase and the  
24 oxidative modifications are introduced by five 2-oxoglutarate-dependent dioxygenases and one  
25 cytochrome P450 monooxygenase. The discovery of the gene cluster enabled the identification  
26 of BCM pathways encoded in the genomes of hundreds of *Pseudomonas aeruginosa* isolates  
27 distributed globally, and heterologous expression of the pathway from *P. aeruginosa* SCV20265  
28 demonstrated that the product is chemically identical to BCM produced by *S. cinnamoneus*.  
29 Overall, putative BCM gene clusters have been found in at least seven genera spanning  
30 *Actinobacteria* and *Proteobacteria* (*Alpha*-, *Beta*- and *Gamma*-). This represents a rare example  
31 of horizontal gene transfer of an intact biosynthetic gene cluster across such distantly related  
32 bacteria, and we show that these gene clusters are almost always associated with mobile genetic  
33 elements.

## 34 **IMPORTANCE**

35 Bicyclomycin is the only natural product antibiotic that selectively inhibits the transcription  
36 termination factor Rho. This mechanism of action, combined with its proven biological safety and  
37 its activity against clinically relevant Gram-negative bacterial pathogens, makes it a very  
38 promising antibiotic candidate. Here, we report the identification of the bicyclomycin  
39 biosynthetic gene cluster in the known producing organism *Streptomyces cinnamoneus*, which

40 will enable the engineered production of new bicyclomycin derivatives. The identification of this  
41 gene cluster also led to the discovery of hundreds of bicyclomycin pathways encoded in highly  
42 diverse bacteria, including the opportunistic pathogen *Pseudomonas aeruginosa*. This wide  
43 distribution of a complex biosynthetic pathway is very unusual, and provides an insight into how  
44 a pathway for an antibiotic can be transferred between diverse bacteria.

## 45 INTRODUCTION

46 Bicyclomycin (BCM) is a broad-spectrum antibiotic active against Gram-negative bacteria that  
47 was first isolated in 1972 from *Streptomyces cinnamoneus* (originally named *Streptomyces*  
48 *sapporoensis*) (1) and is also produced by two other *Streptomyces* species (2, 3). BCM (also known  
49 as bicozamycin) is one of the most complex members of the 2,5-diketopiperazine (DKP) family of  
50 molecules, cyclic dipeptides generated by the head-to-tail condensation of two  $\alpha$ -amino acids  
51 (4). The core DKP of BCM, cyclo(L-Ile-L-Leu) (cIL), is modified with a characteristic second cycle  
52 that forms a [4.2.2] bicyclic unit, an exomethylene group and multiple hydroxylations (5) (Fig.  
53 1A). BCM is a selective inhibitor of the transcription termination factor Rho (6), which is an  
54 essential protein in many bacteria (7, 8) and has been used to treat traveller's diarrhea (9), as  
55 well as in veterinary medicine to treat calves, pigs and fish (7).

56 BCM is the only natural product known to target Rho, which together with its proven safety in  
57 mammals and its activity against clinically relevant ESKAPE pathogens like *Acinetobacter*  
58 *baumannii* and *Klebsiella pneumoniae*, makes it a very attractive antibiotic (7, 10). This promise  
59 is enhanced by the recent discovery that a combination of BCM with bacteriostatic  
60 concentrations of antibiotics targeting protein synthesis leads to a rapid bactericidal synergy (10).

61 Furthermore, structure-activity relationship studies show that BCM potency can be improved  
62 through modification of its exomethylene group (11, 12).

63 In contrast with the extensive knowledge on BCM mechanism of action (6, 7), very little was  
64 known about the biosynthesis of this antibiotic. Feeding experiments previously showed that the  
65 DKP scaffold derives from L-leucine and L-isoleucine, as well as the likely involvement of a  
66 cytochrome P450 monooxygenase in one of the oxidative steps that convert cIL into BCM (13)  
67 (Fig. 1A). To understand BCM biosynthesis, we identified the biosynthetic gene cluster for BCM  
68 in *S. cinnamoneus* DSM 41675, which showed that the DKP core is produced by a cyclodipeptide  
69 synthase (CDPS) (Fig. 1B). This discovery enabled the identification of homologous clusters in  
70 several other species, including hundreds of *Pseudomonas aeruginosa* isolates, an opportunistic  
71 pathogen that causes serious hospital-acquired infections. We prove that the *P. aeruginosa bcm*  
72 gene cluster is functional and its product is identical to BCM from *Streptomyces*, so represents a  
73 viable alternative platform for BCM production. This is a rare example of an almost identical  
74 biosynthetic gene cluster in both Gram-negative and Gram-positive bacteria. An analysis of the  
75 phylogeny and genomic context of *bcm* gene clusters provides an insight into its likely dispersion  
76 through horizontal gene transfer (HGT), and also implies that the *bcm* gene cluster may have  
77 undergone a partial genetic rearrangement between Gram-positive and Gram-negative bacteria.

## 78 **RESULTS AND DISCUSSION**

### 79 **Genome sequencing and identification of the BCM gene cluster in *S. cinnamoneus*.**

80 The genome sequence of a known BCM producer, *S. cinnamoneus* DSM 41675 was obtained using  
81 a combination of Oxford Nanopore MinION and Illumina MiSeq technologies. Illumina MiSeq

82 provided accurate nucleotide level read data, but an Illumina-only assembly was distributed  
83 across 415 contigs, in part due to the difficulties in assembling short read data of highly repetitive  
84 sequences from large modular polyketide synthase (PKS) and non-ribosomal peptide synthetase  
85 (NRPS) genes (14), which were found at the start or end of multiple contigs. Therefore, we also  
86 sequenced the genome using Oxford Nanopore MinION technology, which is capable of achieving  
87 read lengths of over 150 kb (15), The Nanopore output enabled a much better assembly of the  
88 genome over 4 contigs, although at a much lower accuracy at the nucleotide level. Using the raw  
89 read data from both sequence runs, we obtained a hybrid assembly composed of a 6.46 Mb  
90 contig containing almost all of the chromosome, and a smaller 199 kb contig (Table S1).  
91 antiSMASH analysis (16) of this assembly revealed that the 199 kb contig is likely to form part of  
92 the chromosome, as the termini of this contig and the 6.46 Mb contig encode different regions  
93 of an enduracidin-like gene cluster. In total, these two contigs yield an almost contiguous 6.66  
94 Mb *S. cinnamoneus* genome sequence.

95 Published feeding experiments indicate that BCM is a DKP derived from L-leucine and L-isoleucine  
96 and that a cytochrome P450 is likely to be involved in the pathway (13). Furthermore, a number  
97 of additional oxidative reactions are needed to form the final molecule (Fig. 1A). DKPs are  
98 produced naturally by either bimodular NRPSs (17, 18) or by CDPSs (19–21) so we expected the  
99 biosynthetic gene cluster for BCM to encode either of these enzymatic systems, plus six to seven  
100 oxidative enzymes. Analysis of the *S. cinnamoneus* genome sequence with antiSMASH 3.0.5 (16)  
101 indicated that there were no suitable NRPS pathways but also no identifiable CDPS pathways. We  
102 therefore assessed the genomic regions surrounding every P450 gene in the genome, which  
103 revealed the presence of a P450 gene (*bcmD*) that was clustered with genes encoding five 2-

104 oxoglutarate (2OG)-dependent dioxygenases (*bcmB*, *bcmC*, *bcmE*, *bcmF* and *bcmG*), a CPDS gene  
105 (*bcmA*) and a gene encoding a major facilitator superfamily (MFS) transporter (*bcmT*) (Fig 1B).  
106 Both P450s and 2OG-dependent dioxygenases are capable of catalysing the regiospecific and  
107 stereospecific oxidation of non-activated C-H bonds (22–24), while MFS transporters often  
108 function as drug-efflux pumps and can confer antibiotic resistance (25, 26).

109 The putative CDPS (pfam16715) BcmA, has multiple homologs (>45% identity) in other  
110 *Actinobacteria* and, notably, in various *Pseudomonas aeruginosa* strains. Interestingly a homolog  
111 from *P. aeruginosa* (WP\_003158562.1) was previously shown to catalyse the *in vitro* synthesis of  
112 cIL (27), and BcmA contains almost all the same specificity-determining binding pocket residues  
113 as WP\_003158562.1 (Fig. S1). Surprisingly, the five 2OG-dependent dioxygenases encoded in the  
114 cluster share only moderate sequence identity (33 to 45%). In total, the gene cluster encodes six  
115 oxidative enzymes, which is consistent with the number of modifications required to convert cIL  
116 into BCM.

### 117 **Heterologous expression of the *bcm* gene cluster**

118 To test whether the identified gene cluster was indeed responsible and sufficient for the  
119 biosynthesis of BCM, a 7 kb region spanning *bcmA* to *bcmG* was PCR amplified and cloned into  
120 the  $\phi$ BT1 integrative vector pIJ10257 (28) by Gibson assembly (29) to generate pIJ-BCM. This  
121 places the constitutive promoter *ermE*\*p before *bcmA*, which we anticipated would promote the  
122 expression of all *bcm* genes as they are tightly clustered on the same strand. The putative  
123 transporter gene *bcmT* was not included on the basis that several homologs of this gene, as well  
124 as a homolog of the reported BCM resistance gene (30), are present in the *S. coelicolor* genome.

125 pIJ-BCM was introduced into *S. coelicolor* M1146 and M1152 (31) via intergeneric conjugation.  
126 LC-MS<sup>2</sup> analysis of cultures of the resulting strains yielded a peak of *m/z* 285.11 not present in  
127 control strains (Fig. 2), which had an identical retention time and MS<sup>2</sup> fragmentation pattern (*m/z*  
128 211.05, *m/z* 193.2, *m/z* 108.4 and *m/z* 81.9, Fig. S2) to BCM produced by *S. cinnamoneus*, as well  
129 as a pure BCM standard, and corresponds to [BCM-H<sub>2</sub>O+H]<sup>+</sup>. This unambiguously confirmed that  
130 this was the BCM biosynthetic gene cluster. Our result agrees with recent studies by Patteson *et*  
131 *al.* (32) and Meng *et al.* (33) who, in parallel with our study, have reconstituted *in vitro* the  
132 functions of the CDPS and the oxidative steps in the *S. cinnamoneus* pathway.

133 **Identification and heterologous expression of a *bcm* gene cluster from *Pseudomonas***  
134 ***aeruginosa*.**

135 During our bioinformatic analysis of the *S. cinnamoneus* *bcm* gene cluster it became clear that  
136 entire *bcm*-like gene clusters with an apparently identical organisation of *bcmA-G* genes were  
137 present a variety of Gram-negative and Gram-positive bacterial species, and in particular in  
138 multiple *P. aeruginosa* strains. The widespread distribution of such a conserved antibiotic gene  
139 cluster is very rare and prompted us to investigate whether these highly similar gene clusters  
140 actually make identical products. As a representative example, *P. aeruginosa* SCV20265 was  
141 therefore investigated for its ability to produce BCM. This strain is a well-studied (34–36) small  
142 colony variant of the opportunistic pathogen isolated from the lung of a patient with cystic  
143 fibrosis (37) and is considered a reference strain in antibiotic resistance studies (38). The *P.*  
144 *aeruginosa* SCV20265 *bcm*-like gene cluster encodes proteins with sequence identities of  
145 between 30-56% compared to their *Streptomyces* counterparts. A MFS transporter is also

146 encoded in this cluster, but is at the end of the *bcmA-G* operon instead of preceding *bcmA* (Fig.  
147 1B).

148 No BCM production was detected in cultures of *P. aeruginosa* SCV20265, so heterologous  
149 expression of the gene cluster was carried out to determine whether the pathway is functional.  
150 The putative *bcm* cluster (including *bcmT*) was PCR amplified from SCV20265 gDNA and cloned  
151 into pJH10TS (39, 40), which places the putative *bcm* operon under the control of the synthetic  
152 promoter Ptac. *Pseudomonas fluorescens* SBW25 was transformed with the resulting plasmid  
153 (pJH-BCMclp-PA). Several clones of this heterologous expression strain were cultured in a range  
154 of production media, and assessed for their ability to produce BCM. LC-MS<sup>2</sup> analysis revealed  
155 that *P. fluorescens* SBW25-pJH-BCMclp-PA efficiently produces BCM after 14 h of growth (Fig. 3).  
156 The putative BCM detected in these samples exhibited the same retention time, mass and  
157 fragmentation profile as a pure BCM standard, including MS signals of  $m/z$  285.11, as observed  
158 previously, and  $m/z$  325.10, corresponding to [BCM+Na]<sup>+</sup> (Fig. 3 and Figs. S3, S4). This result is  
159 consistent with parallel work from Patteson *et al.* (32), but this does not preclude the possibility  
160 of variation in stereochemistry at one more positions in the molecule. We therefore scaled up  
161 production, purified the compound and subjected it to NMR analysis (<sup>1</sup>H, <sup>13</sup>C, COSY, HMBC,  
162 HSQC), which provided identical spectra (Figs. S5 to S10, Table S2) to authentic BCM reported  
163 previously (41). *Pseudomonas*-produced BCM also had the same optical rotation as a BCM  
164 standard, confirming that they are stereochemically identical.

165 One of the most efficient media for BCM production in *P. fluorescens* was SCFM, a synthetic  
166 medium that mimics the salt and amino acid composition from cystic fibrosis sputum samples  
167 (42). The composition of this medium was simplified to generate bicyclomycin production



168 medium (BCMM), in which cultures of *P. fluorescens* SBW25-pJH-BCMclp-PA provided BCM yields  
169 of  $34.5 \pm 2.1$  mg/L in only 14 h. Interestingly, we could detect at least six additional compounds  
170 in the heterologous expression strain in comparison to a negative control strain harbouring  
171 empty pJH10TS (Fig. 3 and Figs. S3, S4). All of these compounds have masses compatible with  
172 BCM-like compounds (Table S3) and some have BCM-like MS<sup>2</sup> fragmentation patterns, such as a  
173 loss of 74.04 Da that corresponds to fragmentation of the oxidized leucine side chain (Fig. S4).  
174 This production profile makes *P. fluorescens* a promising BCM production system when compared  
175 to the complex media and longer incubation times required to produce BCM in *Streptomyces*  
176 species. In contrast, we could not detect any BCM-like molecules in cultures of wild type *P.*  
177 *aeruginosa* SCV20265, suggesting that additional factors are required to activate the expression  
178 of an otherwise functional gene cluster.

### 179 **Organisation, taxonomic distribution and phylogeny of the *bcm* cluster**

180 The presence of seven contiguous biosynthetic genes that make the same antibiotic in both  
181 Gram-positive and Gram-negative bacteria was a fascinating result. The production of the same  
182 compound in such distantly related organisms (bacteria that are evolutionarily at least 1 billion  
183 years apart (43)) is incredibly rare, but not unprecedented (44). To investigate this unusual result,  
184 a BLASTP search using BcmA was used to identify every putative *bcm* gene cluster (*bcmA-G*) in  
185 sequenced bacterial genomes. In total, 724 candidates were identified, where 31 are found in a  
186 variety of taxa and the remaining sequences all come from *Pseudomonas* species, in particular *P.*  
187 *aeruginosa*. This initial dataset was filtered (see Material and Methods) to generate a final  
188 dataset for phylogenetic analysis containing 374 *bcm*-like gene clusters (Data set S1). Analysis of  
189 this dataset showed that *bcm*-like gene clusters are also found in seven other sequenced

190 *Streptomyces* species besides *S. cinnamoneus*, as well as 20 *Mycobacterium chelonae* strains,  
191 *Williamsia herbipolensis* (order *Corynebacteriales*), *Actinokineospora spheciospongiae* (order  
192 *Pseudonocardiales*) and the Gram-negative bacteria *Burkholderia plantarii* and *Tistrella mobilis*  
193 (*Beta-* and *Alphaproteobacteria*, respectively). Furthermore, a fragmented *bcm*-like gene cluster  
194 was identified in *Photorhabdus temperata* (*Gammaproteobacteria*) by BLAST analysis of BcmA  
195 and the P450 BcmD. This cluster is split across two different contigs (accession numbers  
196 NZ\_AYSJ01000007 and NZ\_AYSJ01000009), where it is accompanied by transposase genes, and  
197 was therefore not included in our dataset.

198 Most *bcm* gene clusters from Gram-positive bacteria share the same gene organisation, with  
199 *bcmT* in a divergent operon upstream of *bcmA*, whereas in all the Gram-negative bacteria (and  
200 *Actinokineospora*) *bcmT* is downstream of *bcmG*. *Streptomyces ossamyceticus* is the only  
201 representative that lacks a transporter gene immediately adjacent to the biosynthetic genes.  
202 Additionally, the MFS transporters from Gram-positive gene clusters only share 27-30% sequence  
203 identity (approx. 40% coverage) with MFS transporters from Gram-negative gene clusters,  
204 suggesting that the transporters have been recruited independently in these distant bacteria.

205 All the *bcm* gene clusters identified in this work were analysed phylogenetically by constructing  
206 a maximum likelihood tree from the nucleotide sequence spanning *bcmA-G*. This showed that  
207 their evolutionary relationship correlates tightly with the taxonomy of the strains (Fig. 4A).  
208 Clusters from Gram-negative (particularly *Pseudomonas*) and Gram-positive bacteria are  
209 grouped in completely independent and distant clades, while the clusters from *Burkholderia* and  
210 *Tristrella* appear at intermediate points between these two groups. Within the Gram-positive  
211 clade, the clusters have a higher degree of divergence but are similarly grouped according to the

212 classification of their native species, with the *Williamsia* gene cluster clustering with the *M.*  
213 *cheloniae* gene clusters (these two genera belong to the order *Corynebacteriales*) (Fig. 4B). All *P.*  
214 *aeruginosa* gene clusters are ~99% identical to each other (Fig. 4A and Fig. S11), whereas the two  
215 most distantly related streptomycete gene clusters share 69% identity and 83% coverage.

#### 216 **Mobile genetic elements associated with *bcm*-like gene clusters**

217 The conserved organisation of biosynthetic genes, along with the phylogenetic relationship  
218 between the *S. cinnamoneus* and *P. aeruginosa* CDPSs (32), strongly implies that the *bcm* gene  
219 cluster has been horizontally transferred between numerous bacteria. The increased sequence  
220 divergence of the *bcm* gene clusters in *Streptomyces* species suggests that the gene cluster may  
221 have originated from this taxonomic group, although it is difficult to prove this hypothesis, as the  
222 gene clusters in all strains appear to have adapted to their hosts, making HGT difficult to infer.  
223 Despite the below average GC content of the clusters (59.6% in *P. aeruginosa* SCV20265 and  
224 70.8% in *S. cinnamoneus*) versus the genome averages (66.3% and 72.4%, respectively), the  
225 clusters were not predicted to be part of genomic islands in these strains when analysed with  
226 IslandViewer4 (45).

227 However, analysis of the genomic context of *bcm* gene clusters in *P. aeruginosa* strains strongly  
228 supports an insertion hypothesis, since the genes that flank the cluster are contiguous in a  
229 number of *P. aeruginosa* strains that lack the cluster (Fig. S12). Most notably, *bcmT* is adjacent  
230 to the glucosamine-fructose-6-phosphate aminotransferase gene *glmS*, and the intergenic region  
231 that precedes *glmS* contains the specific attachment site for transposon Tn7 (*attTn7*) (46).  
232 Consistent with this observation, some strains that lack the *bcm* gene cluster (e.g. *P. aeruginosa*

233 BL08) have mobile genetic elements integrated next to *glmS* (Fig. S12). Intriguingly, many strains,  
234 including the reference strain PAO1, contain a MFS transporter gene (PA5548 in PAO1) adjacent  
235 to *glmS* that is 99% identical with *bcmT* from SCV20265. This either indicates that the *bcm* gene  
236 cluster recently integrated next to an existing *P. aeruginosa* transporter, or that a subset of  
237 strains lost the biosynthetic genes but retained a potential BCM resistance gene.

238 The *bcm*-like gene clusters in other Gram-negative bacteria (*Burkholderia* and *Tistrella*) and most  
239 Gram-positive bacteria are located next to genes coding for integrases, transposases and other  
240 genetic mobility elements, which strongly supports HGT of the cluster into these taxa (Figs. 4B  
241 and 4C). For example, the mycobacterial clusters are found close to tRNA genes, and their  
242 flanking genes are syntenic in some *M. abscessus* strains, whereas in other *M. abscessus* strains  
243 these genes are separated by a cluster of phage-related genes (Fig. 4B and Fig. S13). In the  
244 streptomycetes, the clusters are integrated in different genomic locations, where they are also  
245 often associated with mobile genetic elements (Fig. 4B). Across all genera, this indicates that *bcm*  
246 gene clusters are almost always located at regions of genomic plasticity.

#### 247 **Diversity and geographical distribution of the *bcm* cluster in *P. aeruginosa***

248 The high sequence identity of the *bcm* gene cluster across hundreds of *P. aeruginosa* strains (Fig.  
249 S11) along with its consistent genomic context (Fig. 4C) led us to question whether this cluster is  
250 truly widespread, or only found in a small subset of *P. aeruginosa* strains over-represented in  
251 sequence databases. *P. aeruginosa* isolates have been widely sequenced to evaluate pathogen  
252 diversity and evolution (38, 47, 48). As a result, large collections of sequenced clinical isolates are  
253 available in the databases, potentially constituting a biased dataset that might lead to an

254 overestimation of *bcm* gene cluster abundance and conservation. Most of the sequences in our  
255 final *bcm* dataset come from well-characterised isolate collections. Among them, the Kos  
256 collection (38) provides a comprehensive survey of *P. aeruginosa* diversity, and the *bcm* gene  
257 cluster is present in nearly 20% of isolates sequenced in this collection (74 out of the 390). To  
258 assess the phylogenetic diversity of these strains, we plotted the presence of the *bcm* gene  
259 cluster onto the Kos collection phylogenetic tree (38). Strikingly, this showed that nearly all of  
260 the *bcm*-positive strains are found in the PAO1 clade (Fig. 5), but that these come from very  
261 diverse locations, including the USA, Mexico, Spain, France, Germany, China, Argentina, Brazil,  
262 Colombia, Croatia and Israel, among others. This geographic diversity was further augmented by  
263 an analysis of all *P. aeruginosa* strains encoding the pathway (Data set S1). We can therefore  
264 conclude that the *bcm* gene cluster is distributed globally, but within a phylogenetically distinct  
265 subset of *P. aeruginosa* strains. Given this phylogenetic distribution, it is surprising to note that a  
266 *bcmT* gene is also found next to *glmS* in *P. aeruginosa* PA14 (Fig. S12).

## 267 **2OG-dependent dioxygenase phylogeny**

268 An unusual feature of the *bcm* gene clusters is the presence of five 2OG-dependent dioxygenase  
269 genes. While it is possible that they originally arose by gene duplication events, the *S.*  
270 *cinnamoneus* 2OG-dependent dioxygenases only possess 33-45% sequence identity with each  
271 other (Figure S14). We hypothesised that an analysis of the diversity of the *bcm* 2OG-dependent  
272 dioxygenases across multiple taxa could provide an insight into gene cluster evolution. We  
273 therefore constructed a maximum likelihood tree using protein sequences of every 2OG-  
274 dependent dioxygenase (BcmB, C, E, F and G homologs) from both *S. cinnamoneus* and *P.*

275 *aeruginosa* SCV20265, as well as from other selected *P. aeruginosa* strains and at least one  
276 representative from the other genera that encode *bcm*-like gene clusters.

277 In contrast to the overall gene cluster phylogeny, the *bcm* oxidases group primarily based on their  
278 position in the cluster, and therefore their likely biosynthetic role (Fig. 6). BcmB, BcmC and BcmG  
279 group clearly in different clades, and within these clades the proteins from Gram-negative  
280 bacteria branch out from the Gram-positive subgroups, perhaps indicating the ancestral origin of  
281 these proteins. A surprising result was the unexpected phylogeny of the remaining two 2OG-  
282 dependent dioxygenases, BcmE and BcmF. These are clearly separated into two different clades:  
283 one containing BcmE from Gram-negative bacteria (BcmE-) and BcmF from Gram-positive  
284 bacteria (BcmF+) and one where BcmE+ groups with BcmF-. Within these two clades, Gram-  
285 positive and Gram-negative representatives are more distinct and bifurcate earlier than in the  
286 other clades (Fig. 6). This intriguing result might mean that BcmE and BcmF fulfil inverse roles in  
287 Gram-positive and Gram-negative bacteria, and further experiments are necessary to test this  
288 hypothesis. The phylogenetic relationship between the 2OG-dependent dioxygenases strongly  
289 supports HGT of the cluster between taxa, although the BcmE/BcmF phylogeny indicates that the  
290 cluster may have undergone some reorganisation (Fig. 6).

291 In summary, we demonstrate that the antibiotic BCM is a CDPS-derived natural product whose  
292 biosynthetic gene cluster is present in a diverse array of both Gram-positive and Gram-negative  
293 bacteria. This characterisation was supported by heterologous expression of pathways from *S.*  
294 *cinnamoneus* and *P. aeruginosa*, where the pathway product was proven to be stereochemically  
295 identical to authentic BCM. We have also showed that the previously orphan *P. aeruginosa*  
296 pathway is a promising system for the production of BCM and related derivatives. The *bcm*

297 cluster is dispersed across a number of taxonomically distant bacteria, including *Alpha-*, *Beta-*  
298 and *Gammaproteobacteria*, as well as several *Actinobacteria* families. The widespread presence  
299 of *bcmT* genes in *P. aeruginosa* (even those that lack the biosynthetic genes (Fig. S12)), may  
300 explain why BCM is inactive towards *P. aeruginosa* (49), but further work is required to determine  
301 whether *bcmT* confers BCM resistance.

302 The presence of mobile genetic elements associated with the *bcm* gene cluster in many bacteria  
303 strongly supports dissemination of this gene cluster via HGT, and the diversity of the gene cluster  
304 in Gram-positive bacteria suggests that it then subsequently transferred to Gram-negative  
305 bacteria, where two dioxygenase genes have apparently rearranged in the gene cluster and an  
306 alternative MFS transporter was acquired. However, the opposite direction of horizontal transfer  
307 cannot be ruled out. We are not aware of such a widespread distribution of any other specialized  
308 metabolite gene cluster, although there are examples of compounds that have been found in  
309 both Gram-positive and Gram-negative bacteria, such as pyochelin (50), the coronafacoyl  
310 phytotoxins (51) and furanomycin (52). A recent study by McDonald and Currie showed that It is  
311 very rare to find intact laterally transferred biosynthetic gene clusters, even between  
312 streptomycetes (53).

313 Given this distribution of *bcm* gene clusters, it will be interesting to determine the ecological role  
314 of BCM, especially given the abundance of functional pathways in pathogenic *P. aeruginosa*  
315 strains isolated from lungs, where adaptive evolutionary pressure would have led to the loss or  
316 decay of the cluster unless it conferred a competitive advantage (54). Antibacterial natural  
317 products can have roles in pathogen virulence, such as a bacteriocin produced by the pathogen  
318 *Listeria monocytogenes* that modifies intestinal microbiota to promote infection (55). In addition,

319 given the frequent horizontal transfer of the *bcm* gene cluster and its extensive association with  
320 mobile genetic elements, it is interesting to note that transcription terminator Rho most strongly  
321 represses transcription of horizontally acquired regions of genomes (56), an activity that would  
322 be specifically inhibited by BCM (7). It is known that phages recruit genes from bacteria that  
323 increase their fitness and that of their hosts (57, 58) and this may occur with the *bcm* gene cluster.  
324 These intriguing observations invite further work to determine the natural role of BCM.

325

326

## 327 **MATERIAL AND METHODS**

### 328 **Chemicals and molecular biology reagents**

329 Pharmamedia was obtained from Archer Daniels Midland Company. Antibiotics, and all other  
330 media components and reagents were purchased from Sigma-Aldrich. Bicyclomycin was  
331 purchased from Bioaustralis Fine Chemicals (Australia). Enzymes were purchased from New  
332 England Biolabs unless otherwise specified, and molecular biology kits were purchased from  
333 Promega and GE Healthcare.

### 334 **Bacterial strains, plasmids and culture conditions**

335 *Escherichia coli*, *Streptomyces* and *Pseudomonas* strains, as well as plasmids and oligonucleotides  
336 used or generated in this work are reported in Tables 1 and 2. *S. cinnamoneus* DSM 41675 was  
337 acquired from the German Collection of Microorganisms and Cell Cultures (DSMZ, Germany), *P.*  
338 *aeruginosa* SCV20265 was provided by Prof. Susanne Häussler (Helmholtz Centre for Infection  
339 Research, Germany) and pJH10TS was provided by Prof. Barrie Wilkinson (John Innes Centre, UK).



340 *E. coli* and *Pseudomonas* strains were grown in lysogeny broth (LB) at 37 °C (except for *P.*  
341 *fluorescens* SBW25, which is temperature sensitive and was grown at 28 °C) and stored at -70°C  
342 in 50% glycerol stocks. *Streptomyces* strains were cultured in liquid tryptone soya broth (TSB,  
343 Oxoid) or solid soya flour mannitol (SFM) medium (59) at 28-30 °C and stored at -70 °C as 20%  
344 glycerol spore stocks.

345 The following media were used for bicyclomycin production experiments: Aizunensis production  
346 medium (AIZ), adapted from (60): 20 g/L glucose, 20 g/L soy flour, 2 g/L bactopectone, 2g/L  
347 NaNO<sub>3</sub>, 1 g/L KH<sub>2</sub>PO<sub>4</sub>, 0.5 g/L MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.5 g/L KCl, 0.001 g/L FeSO<sub>4</sub>·7H<sub>2</sub>O, pH 7.0.  
348 Cinnamoneus production medium (CIN), adapted from (1): 20 g/L potato starch, 20 g/L cotton  
349 seed meal (Pharmamedia), 10 g/L soy flour, 5 g/L MgSO<sub>4</sub>·7H<sub>2</sub>O, 10.9 g/L KH<sub>2</sub>PO<sub>4</sub>, 2.85 Na<sub>2</sub>HPO<sub>4</sub>,  
350 pH 6.8 (a solid version of CIN medium with 20 g/L agar was used to grow *S. cinnamoneus* for  
351 reliable spore production). Synthetic cystic fibrosis medium (SCFM) was prepared following the  
352 recipe reported by Kamath and co-workers (42), and an alternative medium optimized for  
353 bicyclomycin production (BCMM) was developed from this (per L): 6.5 mL 0.2 M NaH<sub>2</sub>PO<sub>4</sub>, 6.25  
354 mL 0.2 M Na<sub>2</sub>HPO<sub>4</sub>, 0.348 mL 1 M KNO<sub>3</sub>, 0.122 g NH<sub>4</sub>Cl, 1.114 g KCl, 3.03 g NaCl, 10 mM MOPS,  
355 16.09 mL 100 mM L-leucine, 11.2 mL 100 mM L-isoleucine, 6.33 mL 100 mM L-methionine, 15.49  
356 mL 100 mM L-glutamic acid hydrochloride, 6.76 mL 100 mM L-ornithine·HCl, 1.92 mL 84 mM L-  
357 cystine (dissolved in 0.8 M HCl) and 2 mL 3.6 mM FeSO<sub>4</sub>·7H<sub>2</sub>O, all in milliQ water. The solution  
358 was adjusted to pH 6.8, filter sterilised and supplemented with 0.606 mL 1 M MgCl<sub>2</sub> and 1.754  
359 mL 1 M CaCl<sub>2</sub> (sterilised separately). When necessary, antibiotics were added at the following  
360 concentrations: 50 µg/mL hygromycin, 50 µg/mL apramycin, 50 µg/mL kanamycin, 25 µg/mL  
361 chloramphenicol, 25 µg/mL nalidixic acid and 12.5 µg/mL tetracycline.

362 **Genome sequencing, annotation and bioinformatics analysis of *S. cinnamomeus***

363 Genomic DNA of *S. cinnamomeus* DSM 41675 was isolated following the salting out protocol (59),  
364 which was then subjected to a TruSeq PCR-free library preparation and then sequenced using  
365 Illumina MiSeq (600-cycle, 2x300 bp) at the DNA Sequencing Facility, Department of  
366 Biochemistry, University of Cambridge (UK). MinION nanopore sequencing (Oxford Nanopore  
367 Technologies, UK) was carried out using the following protocol.

368 A single colony from *S. cinnamomeus* grown on solid CIN medium was used to inoculate 50 mL  
369 TSB, which was incubated at 28 °C overnight with shaking at 250 rpm. 1 mL of this seed culture  
370 was used to inoculate a further 50 mL TSB, which was again incubated at 28 °C overnight with  
371 shaking at 250 rpm. DNA was extracted from 10 mL of this culture using the salting out procedure  
372 as described before (59) and resuspended in 5 mL Tris-EDTA (TE) buffer. DNA concentration was  
373 quantified using a Qubit 2.0 Fluorometer (Life Technologies) and fragment length and DNA  
374 quality was assessed using the Agilent TapeStation 2200 (Agilent Technologies).

375 Genomic DNA (~11 µg in 100 µL) was fragmented using a Covaris g-TUBE (Covaris, UK) centrifuged  
376 at 3380 x g for 90 s x 2 to achieve a fragment distribution with a peak at ~16 kb. The sequencing  
377 library was prepared using Oxford Nanopore Technologies Nanopore Sequencing Kit SQK-NSK007  
378 (R9 version) according to the manufacturer's protocol (16 May 2016 version) starting at the End-  
379 prep step with ~2.5 ng of DNA. Half (12 µL) of the library was loaded onto a FLO-Min104 (R9  
380 version) flow cell and sequenced for ~22 hours using the script: MinKNOW  
381 NC\_48hr\_Sequencing\_Run\_FLO-Min104.py. The flow cell was re-started after ~7 hours. The  
382 remaining 12 µL of the library was loaded after re-starting the flow cell at 22 hours. Sequencing

383 was then run for a further 43 hours. Base-calling was performed using Metrichor Desktop Agent  
384 (v1.107, 2D basecalling for SQK-NSK007).

385 The complete, raw data set comprised 7,044,217 paired-end 301 bp Illumina MiSeq reads and  
386 53,048 QC-passed Nanopore MinION reads. The Nanopore reads were extracted to fastq format  
387 using the poRe R package (61). For the Illumina-only assembly, SPAdes v3.6.2 (62) was used with  
388 the *k*-mer flag set to -k 21,33,55,77,99,127. For the Nanopore-only assembly, Canu v1.5 (63) was  
389 used with genomesize=7.0m and the `--nanopore-raw` flag. For the hybrid Illumina/Nanopore  
390 assembly, SPAdes v3.8.2 (64) was used, supplied with both datasets and with the `--careful` and `--`  
391 `nanopore` flags. Contigs with low sequence coverage were removed from the hybrid assembly.  
392 All assembly tasks were conducted using 16 CPUs on a 256 GB compute node within the Norwich  
393 Bioscience Institutes (NBI) High Performance Computing (HPC) cluster. Genome assembly  
394 statistics are reported in Table S1. The hybrid assembly genome sequence was annotated using  
395 Prokka (65), which implements Prodigal (66) as an *orf* calling tool.

#### 396 **Cloning the *S. cinnamoneus bcm* gene cluster**

397 The DNA region containing the *bcm* gene cluster was PCR amplified from *S. cinnamoneus* gDNA  
398 using primers pIJ-bcm\_start and pIJ-bcm\_end with Herculase II Fusion DNA polymerase (Agilent).  
399 The resulting 6981 bp fragment was gel purified and inserted via Gibson assembly (29) into  
400 pIJ10257 (a  $\Phi$ BT1 integrative and hygromycin resistant vector (28)) linearized with NdeI and PacI  
401 to generate plasmid pIJ-BCM. To verify that the cluster sequence in this construct was correct,  
402 the plasmid was Sanger sequenced using primers BCM\_seq\_1 to BCM\_seq\_8. All other DNA  
403 isolation and manipulation techniques were performed according to standard procedures (67).

404 **Genetic manipulation of *Streptomyces* and heterologous expression of the *bcm* cluster**

405 Methylation-deficient *E. coli* ET12567 carrying the helper plasmid pUZ8002 (68) was transformed  
406 with pIJ-BCM by electroporation. This was employed as the donor strain in an intergeneric  
407 conjugation with *S. coelicolor* M1146 and M1152 (31), which was performed following standard  
408 protocols (59). Exconjugants were screened by colony PCR with primers bcm-cdps\_chk\_fw and  
409 bcm-cdps\_chk\_rv to confirm plasmid integration. Control strains containing empty pIJ10257  
410 were also generated using the same methodology.

411 **Cloning and expression of the *P. aeruginosa bcm* gene cluster**

412 Genomic DNA of *P. aeruginosa* SCV20265 was obtained using the FastDNA SPIN Kit for Soil (MP  
413 Biomedicals). The DNA region containing genes *bcmA* to *bcmT* preceded by their own native  
414 promoter was PCR amplified using primers pJH-BCMclp\_start and pJH-BCMcl\_end with Herculase  
415 II Fusion DNA polymerase (Agilent). The resulting 8604 bp fragment was gel purified and inserted  
416 via Gibson assembly (29) into pJH10TS (a derivative of the broad-host-range IncQ expression  
417 vector pJH10 carrying the synthetic Tac promoter(39, 40)) linearized with NdeI and XbaI to  
418 generate expression plasmid pJH-BCMclp-PA. This plasmid was verified by Sanger sequencing  
419 with primers BCM\_PA\_seq\_1 to BCM\_PA\_seq\_9 and introduced into *P. fluorescens* SBW25 via  
420 electroporation of freshly made competent cells, which were prepared as follows: two 1 mL  
421 aliquots of an overnight culture of *P. fluorescens* were centrifuged at 11,000 x *g* for 1 min, and  
422 the pellets washed three times with 1 mL of HEPES buffer each, centrifuging at 11,000 x *g* for 1  
423 min in every wash. The two pellets were then merged and resuspended in 100 µL HEPES buffer  
424 and 2 µL of plasmid prep were added to the cell suspension, which was electroporated applying

425 2500 V. After electroporation, the suspension was transferred to 1 mL of fresh LB and incubated  
426 with shaking at 28 °C for 1 hour after which 100 µL of the mixture were plated onto an LB plate  
427 containing 12.5 µg/mL tetracycline. As a negative control, the empty vector pJH10TS (40) was  
428 also transformed into *P. fluorescens* SBW25. In order to verify the presence and sequence  
429 accuracy of the construct in *P. fluorescens*, colony PCR was carried out with transformants using  
430 primers pJH\_chk\_fw and pJH\_chk\_rv. For the positive clones selected for downstream work, pJH-  
431 BCMclp-PA was recovered and sequenced with primers BCM\_PA\_seq\_1 to BCM\_PA\_seq\_9.

#### 432 **Production and LC-MS analysis of BCM**

433 30 µL of a concentrated stock of *S. cinnamoneus* spores were used to inoculate 10 mL AIZ medium  
434 in 50 mL flasks, which were incubated at 28 °C with shaking at 250 rpm for 3 days. 500 µL of this  
435 seed culture were used to inoculate 7 mL CIN medium in 50 mL Falcon tubes covered with foam  
436 bungs. These production cultures were incubated at 28 °C with shaking at 250 rpm for 4 days.  
437 The same procedure was used for *S. coelicolor* M1146-pIJ-BCM and M1152-pIJ-BCM. For  
438 production in *P. fluorescens*, 20 µL of cell stocks were used to inoculate 10 mL SCFM in 30 mL  
439 universal polystyrene tubes. These cultures were grown overnight at 28 °C with shaking at 250  
440 rpm, with the screw caps slightly loose to allow aeration, and 400 µL aliquots were used to  
441 inoculate 10 mL BCMM in 50 mL Falcon tubes covered with foam bungs. Production cultures were  
442 incubated for 12-16 h at 28 °C with shaking at 250 rpm.

443 For the analysis of BCM production, 1 mL production culture samples were centrifuged at 18,000  
444 x *g* for 5 minutes. 5 µL of these samples were analysed by LC-MS using a Luna Omega 1.6 µm  
445 Polar C18 column (50 mm x 2.1 mm, 100 Å, Phenomenex) connected to a Shimadzu Nexera X2

446 UHPLC eluting with a linear gradient of 0 to 35% methanol in water + 0.1% formic acid over 6  
447 minutes, with a flow-rate of 0.5 mL/min. MS data was obtained using a Shimadzu ion-trap time-  
448 of-flight (IT-TOF) mass spectrometer coupled to the UHPLC and analysed using LabSolutions  
449 software (Shimadzu). MS data was collected in positive mode over a 200-2000  $m/z$  range, with  
450 an ion accumulation window of 10 ms and automatic sensitivity control of 70% of the base peak.  
451 The curved desolvation line (CDL) temperature was 250 °C and the heat block temperature was  
452 300 °C. MS<sup>2</sup> data was collected between  $m/z$  90 and 2000 in a data-dependent manner for parent  
453 ions between  $m/z$  200 and 1500, using collision-induced dissociation energy of 50% and a  
454 precursor ion width of 3 Da. The instrument was calibrated using sodium trifluoroacetate cluster  
455 ions prior to every run.

456 Additional LC-MS analysis was carried out using a Waters Xevo TQ-S Tandem LC-MS fitted with  
457 the aforementioned column and employing the same chromatographic method, but injecting 1  
458  $\mu$ L sample. A multiple reaction monitoring (MRM) method for BCM identification and  
459 quantification was configured with Intellistart software (Waters) using pure BCM as a standard.  
460 The following transitions were monitored over a dwell time of 0.01 s each (collision energies  
461 applied in each case are listed in brackets): for the parent ion with  $m/z$  285.11  $[M-H_2O+H]^+$  :  
462 211.04 (16 V), 193.28 (20 V), 108.13 (28 V) and 81.93 (34 V). For the parent ion with  $m/z$  325.10  
463  $[M+Na]^+$ : 307.07 (16 V), 251.07 (16 V), 233.18 (20 V) and 215.96 (22 V). Data was acquired in  
464 positive electrospray mode with a capillary voltage of 3.9 kV, desolvation temperature of 500 °C  
465 and gas flow of 900 L/h, cone gas flow of 150 L/h and nebuliser set to 7.0 bar. LC-MS data were  
466 analysed using MassLynx software and the quantification tool QuanLynx (Waters). Xevo MS peak  
467 areas were used to determine BCM yields in comparison to a BCM standard.

468 For the accurate mass measurement of the BCM-like compounds high-resolution mass spectra  
469 were acquired on a Synapt G2-Si mass spectrometer (Waters) operated in positive mode with a  
470 scan time of 0.5 s in the mass range of  $m/z$  50 to 600. 5  $\mu$ L samples were injected onto a Luna  
471 Omega 1.6  $\mu$ m Polar C18 column (50 mm x 2.1 mm, 100  $\text{\AA}$ , Phenomenex) and eluted with a linear  
472 gradient of 1 to 40% acetonitrile in water + 0.1% formic acid over 7 minutes. Synapt G2-Si MS  
473 data were collected with the following parameters: capillary voltage = 2.5 kV; cone voltage = 40  
474 V; source temperature = 120  $^{\circ}$ C; desolvation temperature = 350  $^{\circ}$ C. Leu-enkephalin peptide was  
475 used to generate a dual lock-mass calibration with  $m/z$  = 278.1135 and  $m/z$  = 556.2766 measured  
476 every 30 s during the run.

#### 477 **Isolation and characterization of BCM from *Pseudomonas***

478 4 X 2L flasks containing 500 mL of BCMM were each inoculated with 20 mL of SBW25-pJH-  
479 BCMclp-PA SCFM seed culture grown overnight. After 20 h fermentation at 28  $^{\circ}$ C with shaking at  
480 250 rpm, the culture broth (approx. 2 L) was separated from the cells by centrifugation to yield a  
481 cell-free supernatant (ca. 2 L). The supernatant was lyophilized and then resuspended in distilled  
482 water (0.6 L). This aqueous solution was extracted with ethyl acetate (3 x 0.6 L) and then with 1-  
483 butanol (3 x 3 L). The solvent was removed to dryness from each extract to afford an ethyl acetate  
484 extract (0.014 g), a butanol extract (0.914 g) and an aqueous extract (7.06 g). LC-MS analysis  
485 determined that the target compounds were mainly in the butanol and the aqueous extracts.  
486 0.202 g of the aqueous extract and all of the butanol extract were subjected to solid phase  
487 chromatography (SPE) on a C-18 cartridge (DSC-18, 20 mL) using a gradient of H<sub>2</sub>O : MeOH (100:0  
488 to 80:20). Fractions containing BCM were combined and further purified by semi-preparative  
489 HPLC (Phenomenex, Luna PFP(2), 250 mm x 10 mm, 5  $\mu$ m; 2 mL/min, UV detection at 218 nm)

490 using a linear gradient of MeOH/H<sub>2</sub>O from 2 to 35% MeOH over 35 minutes, yielding bicyclomycin  
491 (3.3 mg,  $t_R$  30.2 min). 1D and 2D NMR spectra were recorded at a <sup>1</sup>H resonance frequency of 400  
492 MHz and a <sup>13</sup>C resonance frequency of 100 MHz using a Bruker Avance 400 MHz NMR  
493 spectrometer operated using Topspin 2.0 software. Spectra were calibrated to the residual  
494 solvent signals of CD<sub>3</sub>SOCD<sub>3</sub> with resonances at  $\delta_H$  2.50 and  $\delta_C$  39.52. Optical rotations were  
495 measured on a PerkinElmer Polarimeter (Model 341) using the sodium D line (589 nm) at 20 °C.  
496 Commercial standard BCM:  $[\alpha]_D^{20} +42.8^\circ$  (c 0.454, MeOH). *Pseudomonas* BCM:  $[\alpha]_D^{20} +43.5^\circ$  (c  
497 0.091, MeOH).

#### 498 **Identification of *bcm* gene clusters in sequenced bacteria**

499 The sequences used for the phylogenetic analyses performed in this work were retrieved as  
500 follows. A BLASTP search against the NCBI non-redundant protein sequence database was carried  
501 out using the CDPS BcmA from *S. cinnamomeus* as the query, and the accession numbers of the  
502 resulting 73 hits were retrieved. These accession numbers were then used as input for Batch  
503 Entrez (<https://www.ncbi.nlm.nih.gov/sites/batchentrez>) to retrieve all the genomic records  
504 associated to them in the RefSeq nucleotide database (i.e. genomic sequences containing the  
505 protein IDs recovered from BLASTP). This yielded a total of 754 nucleotide records which were  
506 then analysed using MultiGeneBlast (69) to ascertain which ones had the complete *bcm* gene  
507 cluster. 30 of the 754 sequences were discarded on the basis that they did not contain the *bcm*  
508 gene cluster or its sequence was truncated. Analysis of the metadata associated with the  
509 remaining records lead to the exclusion of 217 *P. aeruginosa* sequences (accession numbers  
510 NZ\_LCSU01000019.1 to NZ\_LFDI01000014.1, ordered by taxonomic ID) in order to avoid  
511 overestimation of the cluster conservation, since they were all isolated from a single patient (70).



512 An additional 134 *P. aeruginosa* sequences (accession numbers NZ\_FRFJ01000027.1 to  
513 NZ\_FUEJ01000078.1, ordered by taxonomic ID) were also excluded from the analysis, due to a  
514 lack of associated metadata that prevented an assessment of the diversity of the sample set.  
515 Finally, a sequence from accession number NZ\_LL0001000091.1 was also discarded due to the  
516 presence of a stretch of undetermined nucleotides (substituted with Ns) in the *bcm* gene cluster.  
517 This resulted in a final dataset of 374 sequences: 372 putative *bcm* gene clusters (Data set S1)  
518 plus the gene clusters from *S. cinnamomeus* DSM 41675 and *P. aeruginosa* SCV20265. For the  
519 downstream formatting of the dataset sequences, scripts or programs that could be run in  
520 parallel to process multiple inputs were run via GNU Parallel (71).

#### 521 **Phylogenetic analysis of the *bcm* gene cluster**

522 Nucleotide sequences of the 374 dataset clusters were trimmed to span a nucleotide region from  
523 200 bp upstream of the start of *bcmA* to 200 bp downstream of the end of *bcmG* (average length  
524 of 7224 bp). Phylogenetic analyses were carried out using MUSCLE and RAxML, which were used  
525 through the CIPRES science gateway (72) and T-REX (73), and the trees were visualised and edited  
526 using iTOL (74).

527 The 374 trimmed *bcm* gene cluster sequences were aligned using MUSCLE (75) with the following  
528 parameters: muscle -in infile.fasta -seqtype dna -maxiters 2 -maxmb 30000000 -log logfile.txt -  
529 verbose -weight1 clustalw -cluster1 upgmb -sueff 0.1 -root1 pseudo -maxtrees 1 -weight2  
530 clustalw -cluster2 upgmb -sueff 0.1 -root2 pseudo -objscore sp -noanchors -phyiout outputi.phy  
531 The resulting PHYLIP interleaved output file was then used to generate a maximum likelihood  
532 phylogenetic tree using RAxML (76). The program was configured to perform rapid bootstrapping

533 (BS) with up to a maximum 1000 BS replicate searches (or until convergence was reached),  
534 followed by a maximum likelihood search to identify the best tree, with the following input  
535 parameters: Raxml -T 4 -N autoMRE -n correctorientcluster -s infile.txt -c 25 -m GTRCAT -p 12345  
536 -k -f a -x 12345

537 During the phylogenetic analysis with RAxML, 225 sequences were found to be absolutely  
538 identical, and were subsequently removed to allow for a streamlined analysis of cluster  
539 phylogeny. After the analysis, sequence with accession number NZ\_LLQO01000184.1 was also  
540 found to be truncated and was eliminated from the phylogenetic tree, which contained 148 non-  
541 redundant entries.

542 For the phylogenetic analyses of the 2-OG-dependent dioxygenases, the amino acid sequences of  
543 BcmB, BcmC, BcmE, BcmF and BcmG from *S. cinnamoneus*, *P. aeruginosa* SCV20265 and a strain  
544 subset including all representatives from *Streptomyces*, *Actinokineospora*, *Williamsia*,  
545 *Burkholderia* and *Tistrella*, as well as two from *Mycobacterium* and seven from *Pseudomonas*,  
546 were retrieved, aligned with MUSCLE (with same parameters as before except for -seqtype  
547 protein -hydro 5 -hydrofactor 1.2) and a maximum likelihood phylogenetic tree was generated  
548 with RAxML using the model -m PROTGAMMABLOSUM62, including protein BP3529 from  
549 *Bordetella pertussis* (accession ID POA3X2.1) as an outgroup.

#### 550 **Analysis of the genomic context of the *bcm* gene cluster**

551 For all of the sequences containing the *bcm* gene cluster, a 20 kb region around BcmA was  
552 retrieved and reannotated using Prokka. A subset of these sequences (all Gram-positive bacteria,

553 plus *Burkholderia*, *Tistrella* and several *Pseudomonas* strains) were analyzed for conserved  
554 domains using CDD at NCBI (77) and mobile genetic elements were identified by manual analysis.

#### 555 **Accession number**

556 The genome sequence of *S. cinnamoneus* DSM 41675 has been deposited in the GenBank  
557 database (<https://www.ncbi.nlm.nih.gov/GenBank/>) with the BioProject ID PRJNA423036.

558

#### 559 **ACKNOWLEDGEMENTS**

560 This work was supported by Medical Research Council Newton Fund grant MR/P007570/1  
561 (A.W.T, N.M.V and R.L), a Royal Society University Research Fellowship (A.W.T), Biotechnology  
562 and Biological Sciences Research Council Institute Strategic Programme Grants BB/J004561/1  
563 and BB/P012523/1 to the John Innes Centre (A.W.T. and N.M.V), and the NBI Computing  
564 infrastructure for Science group through use of its HPC cluster. We would like to thank Susanne  
565 Häussler (Helmholtz Centre for Infection Research, Germany) for providing *P. aeruginosa*  
566 SCV20265, Jacques Corbeil (CRCHU de Québec-Université Laval, Canada) for providing the Kos  
567 collection phylogenetic tree and Barrie Wilkinson (John Innes Centre, UK) for access to MinION  
568 equipment and for providing pJH10TS.

569

570

571

572

573 **REFERENCES**

- 574 1. Miyoshi T, Miyairi N, Aoki H, Kohsaka M, Sakai H, Imanaka H. 1972. Bicyclomycin, a new  
575 antibiotic. I. Taxonomy, isolation and characterization. J Antibiot 25:569–575.
- 576 2. Miyamura S, Ogasawara N, Otsuka H, Niwayama S, Tanaka H, Take T, Uchiyama T, Ochiai  
577 H. 1973. Antibiotic 5879 produced by *Streptomyces aizunensis*, identical with  
578 bicyclomycin. J Antibiot 26:479–484.
- 579 3. Ochi K, Saito Y, Umehara K, Ueda I, Kohsaka M. 1984. Restoration of aerial mycelium and  
580 antibiotic production in a *Streptomyces griseoflavus* arginine auxotroph. Microbiology  
581 130:2007–2013.
- 582 4. Borthwick AD. 2012. 2,5-Diketopiperazines: Synthesis, Reactions, Medicinal Chemistry,  
583 and Bioactive Natural Products. Chem Rev 112:3641–3716.
- 584 5. Kamiya T, Maeno S, Hashimoto M, Mine Y. 1972. Bicyclomycin, a new antibiotic. II.  
585 Structural elucidation and acyl derivatives. J Antibiot 25:576–581.
- 586 6. Skordalakes E, Brogan AP, Park BS, Kohn H, Berger JM. 2005. Structural Mechanism of  
587 Inhibition of the Rho Transcription Termination Factor by the Antibiotic Bicyclomycin.  
588 Structure 13:99–109.
- 589 7. Kohn H, Widger W. 2005. The Molecular Basis for the Mode of Action of Bicyclomycin.  
590 Curr Drug Targets - Infect Disord 5:273–295.
- 591 8. Washburn RS, Gottesman ME. 2011. Transcription termination maintains chromosome  
592 integrity. Proc Natl Acad Sci U S A 108:792–797.

- 593 9. Harford PS, Murray BE, DuPont HL, Ericsson CD. 1983. Bacteriological studies of the  
594 enteric flora of patients treated with bicozamycin (CGP 3543/E) for acute nonparasitic  
595 diarrhea. *Antimicrob Agents Chemother* 23:630–633.
- 596 10. Malik M, Li L, Zhao X, Kerns RJ, Berger JM, Drlica K. 2014. Lethal synergy involving  
597 bicyclomycin: an approach for reviving old antibiotics. *J Antimicrob Chemother* 69:3227–  
598 3235.
- 599 11. Brogan AP, Widger WR, Bensadek D, Riba-Garcia I, Gaskell SJ, Kohn H. 2005.  
600 Development of a Technique to Determine Bicyclomycin-Rho Binding and Stoichiometry  
601 by Isothermal Titration Calorimetry and Mass Spectrometry. *J Am Chem Soc* 127:2741–  
602 2751.
- 603 12. Park B-S, Widger W, Kohn H. 2006. Fluorine-substituted dihydrobicyclomycins: Synthesis  
604 and biochemical and biological properties. *Bioorg Med Chem* 14:41–61.
- 605 13. Bradley EL, Herbert RB, Lawrie KWM, Khan JA, Moody CM, Young DW. 1996. The  
606 biosynthesis of the *Streptomyces* antibiotic bicyclomycin. *Tetrahedron Lett* 37:6935–  
607 6938.
- 608 14. Gomez-Escribano JP, Alt S, Bibb MJ. 2016. Next Generation Sequencing of Actinobacteria  
609 for the Discovery of Novel Natural Products. *Mar Drugs* 14:78.
- 610 15. Jain M, Olsen HE, Paten B, Akeson M. 2016. The Oxford Nanopore MinION: delivery of  
611 nanopore sequencing to the genomics community. *Genome Biol* 17:239.
- 612 16. Weber T, Blin K, Duddela S, Krug D, Kim HU, Bruccoleri R, Lee SY, Fischbach MA, Müller R,

- 613 Wohlleben W, Breitling R, Takano E, Medema MH. 2015. antiSMASH 3.0—a  
614 comprehensive resource for the genome mining of biosynthetic gene clusters. *Nucleic  
615 Acids Res* 43:W237–W243.
- 616 17. Cramer RA, Gamcsik MP, Brooking RM, Najvar LK, Kirkpatrick WR, Patterson TF, Balibar  
617 CJ, Graybill JR, Perfect JR, Abraham SN, Steinbach WJ, Steinbach WJ. 2006. Disruption of  
618 a nonribosomal peptide synthetase in *Aspergillus fumigatus* eliminates gliotoxin  
619 production. *Eukaryot Cell* 5:972–980.
- 620 18. King RR, Calhoun LA. 2009. The thaxtomin phytotoxins: Sources, synthesis, biosynthesis,  
621 biotransformation and biological activity. *Phytochemistry* 70:833–841.
- 622 19. Gondry M, Sauguet L, Belin P, Thai R, Amouroux R, Tellier C, Tuphile K, Jacquet M, Braud  
623 S, Courçon M, Masson C, Dubois S, Lautru S, Lecoq A, Hashimoto S, Genet R, Pernodet J-  
624 L. 2009. Cyclodipeptide synthases are a family of tRNA-dependent peptide bond-forming  
625 enzymes. *Nat Chem Biol* 5:414–420.
- 626 20. Bonnefond L, Arai T, Sakaguchi Y, Suzuki T, Ishitani R, Nureki O. 2011. Structural basis for  
627 nonribosomal peptide synthesis by an aminoacyl-tRNA synthetase paralog. *Proc Natl  
628 Acad Sci U S A* 108:3912–3917.
- 629 21. James ED, Knuckley B, Alqahtani N, Porwal S, Ban J, Karty JA, Viswanathan R, Lane AL.  
630 2016. Two Distinct Cyclodipeptide Synthases from a Marine Actinomycete Catalyze  
631 Biosynthesis of the Same Diketopiperazine Natural Product. *ACS Synth Biol* 5:547–553.
- 632 22. Werck-Reichhart D, Feyereisen R. 2000. Cytochromes P450: a success story. *Genome Biol*

- 633 1:reviews3003.1–3003.9.
- 634 23. Farrow SC, Facchini PJ. 2014. Functional diversity of 2-oxoglutarate/Fe(II)-dependent  
635 dioxygenases in plant metabolism. *Front Plant Sci* 5:524.
- 636 24. Martinez S, Hausinger RP. 2015. Catalytic Mechanisms of Fe(II)- and 2-Oxoglutarate-  
637 dependent Oxygenases. *J Biol Chem* 290:20702–20711.
- 638 25. Quistgaard EM, Low C, Guettou F, Nordlund P. 2016. Understanding transport by the  
639 major facilitator superfamily (MFS): structures pave the way. *Nat Rev Mol Cell Biol*  
640 17:123–132.
- 641 26. Kumar S, He G, Kakarla P, Shrestha U, KC R, Ranaweera I, Mark Willmon T, R Barr S, J  
642 Hernandez A, F Varela M. 2016. Bacterial multidrug efflux pumps of the major facilitator  
643 superfamily as targets for modulation. *Infect Disord Drug Targets* 16:28–43.
- 644 27. Jacques IB, Moutiez M, Witwinowski J, Darbon E, Martel C, Seguin J, Favry E, Thai R,  
645 Lecoq A, Dubois S, Pernodet J-L, Gondry M, Belin P. 2015. Analysis of 51 cyclodipeptide  
646 synthases reveals the basis for substrate specificity. *Nat Chem Biol* 11:721–727.
- 647 28. Hong H-J, Hutchings MI, Hill LM, Buttner MJ. 2005. The role of the novel Fem protein  
648 VanK in vancomycin resistance in *Streptomyces coelicolor*. *J Biol Chem* 280:13055–61.
- 649 29. Gibson DG, Young L, Chuang R-Y, Venter JC, Hutchison CA, Smith HO. 2009. Enzymatic  
650 assembly of DNA molecules up to several hundred kilobases. *Nat Methods* 6:343–345.
- 651 30. Bentley J, Hyatt LS, Ainley K, Parish JH, Herbert RB, White GR. 1993. Cloning and  
652 sequence analysis of an *Escherichia coli* gene conferring bicyclomycin resistance. *Gene*

- 653 127:117–120.
- 654 31. Gomez-Escribano JP, Bibb MJ. 2011. Engineering *Streptomyces coelicolor* for  
655 heterologous expression of secondary metabolite gene clusters. *Microb Biotechnol*  
656 4:207–215.
- 657 32. Patteson JB, Cai W, Johnson RA, Santa Maria KC, Li B. 2017. Identification of the  
658 Biosynthetic Pathway for the Antibiotic Bicyclomycin. *Biochemistry* DOI:  
659 10.1021/acs.biochem.7b00943
- 660 33. Meng S, Han W, Zhao J, Jian X-H, Pan H-X, Tang G-L. 2017. A Six-Oxidase Cascade for  
661 Tandem C–H Bond Activation Revealed by Reconstitution of Bicyclomycin Biosynthesis.  
662 *Angew Chem Int Ed* DOI: 10.1002/anie.201710529
- 663 34. Wehmhöner D, Häussler S, Tümmler B, Jänsch L, Bredenbruch F, Wehland J, Steinmetz I.  
664 2003. Inter- and intracolonial diversity of the *Pseudomonas aeruginosa* proteome  
665 manifests within the secretome. *J Bacteriol* 185:5807–5814.
- 666 35. von Götz F, Häussler S, Jordan D, Saravanamuthu SS, Wehmhöner D, Strüssmann A,  
667 Lauber J, Attree I, Buer J, Tümmler B, Steinmetz I. 2004. Expression analysis of a highly  
668 adherent and cytotoxic small colony variant of *Pseudomonas aeruginosa* isolated from a  
669 lung of a patient with cystic fibrosis. *J Bacteriol* 186:3837–3847.
- 670 36. Eckweiler D, Bunk B, Spröer C, Overmann J, Häussler S. 2014. Complete Genome  
671 Sequence of Highly Adherent *Pseudomonas aeruginosa* Small-Colony Variant SCV20265.  
672 *Genome Announc* 2:e01232-13.



- 673 37. Häussler S, Ziegler I, Löttel A, Götz F v., Rohde M, Wehmhöhner D, Saravanamuthu S,  
674 Tümmler B, Steinmetz I. 2003. Highly adherent small-colony variants of *Pseudomonas*  
675 *aeruginosa* in cystic fibrosis lung infection. J Med Microbiol 52:295–301.
- 676 38. Kos VN, Déraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, Corbeil J, Gardner H.  
677 2015. The Resistome of *Pseudomonas aeruginosa* in Relationship to Phenotypic  
678 Susceptibility. Antimicrob Agents Chemother 59:427–436.
- 679 39. El-Sayed AK, Hothersall J, Cooper SM, Stephens E, Simpson TJ, Thomas CM. 2003.  
680 Characterization of the mupirocin biosynthesis gene cluster from *Pseudomonas*  
681 *fluorescens* NCIMB 10586. Chem Biol 10:419–430.
- 682 40. Scott TA, Heine D, Qin Z, Wilkinson B. 2017. An L-threonine transaldolase is required for  
683 L-threo- $\beta$ -hydroxy- $\alpha$ -amino acid assembly during obafluorin biosynthesis. Nat Commun  
684 8:15935.
- 685 41. Kohn H, Abuzar S, Korp JD, Zektzer AS, Martin GE. 1988. Structural studies of  
686 bicyclomycin. J Heterocyclic Chem 25:1511–1517.
- 687 42. Kamath KS, Pascovici D, Penesyan A, Goel A, Venkatakrishnan V, Paulsen IT, Packer NH,  
688 Molloy MP. 2016. *Pseudomonas aeruginosa* Cell Membrane Protein Expression from  
689 Phenotypically Diverse Cystic Fibrosis Isolates Demonstrates Host-Specific Adaptations. J  
690 Proteome Res 15:2152–2163.
- 691 43. Marin J, Battistuzzi FU, Brown AC, Hedges SB. 2017. The Timetree of Prokaryotes: New  
692 Insights into Their Evolution and Speciation. Mol Biol Evol 34:437–446.

- 693 44. Masschelein J, Jenner M, Challis GL. 2017. Antibiotics from Gram-negative bacteria: a  
694 comprehensive overview and selected biosynthetic highlights. *Nat Prod Rep* 34:712–783.
- 695 45. Bertelli C, Laird MR, Williams KP, Lau BY, Hoad G, Winsor GL, Brinkman FSL. 2017.  
696 IslandViewer 4: expanded prediction of genomic islands for larger-scale datasets. *Nucleic*  
697 *Acids Res* 45:W30–W35.
- 698 46. Choi K-H, Gaynor JB, White KG, Lopez C, Bosio CM, Karkhoff-Schweizer RR, Schweizer HP.  
699 2005. A Tn7-based broad-range bacterial cloning and expression system. *Nat Methods*  
700 2:443–448.
- 701 47. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras J-B, Barbu EM, Shortridge D,  
702 Blanc B, Hannum G, Zambardi G, Miller K, Enright MC, Mugnier N, Bami D, Schicklin S,  
703 Felderman M, Schwartz AS, Richardson TH, Peterson TC, Hubby B, Cady KC. 2015.  
704 Phylogenetic Distribution of CRISPR-Cas Systems in Antibiotic-Resistant  
705 *Pseudomonas aeruginosa*. *mBio* 6:e01796-15.
- 706 48. Freschi L, Jeukens J, Kukavica-Ibrulj I, Boyle B, Dupont M-J, Laroche J, Larose S, Maaroufi  
707 H, Fothergill JL, Moore M, Winsor GL, Aaron SD, Barbeau J, Bell SC, Burns JL, Camara M,  
708 Cantin A, Charette SJ, Dewar K, Déziel É, Grimwood K, Hancock REW, Harrison JJ, Heeb S,  
709 Jelsbak L, Jia B, Kenna DT, Kidd TJ, Klockgether J, Lam JS, Lamont IL, Lewenza S, Loman N,  
710 Malouin F, Manos J, McArthur AG, McKeown J, Milot J, Naghra H, Nguyen D, Pereira SK,  
711 Perron GG, Pirnay J-P, Rainey PB, Rousseau S, Santos PM, Stephenson A, Taylor V, Turton  
712 JF, Waglechner N, Williams P, Thrane SW, Wright GD, Brinkman FSL, Tucker NP, Tümmler  
713 B, Winstanley C, Levesque RC. 2015. Clinical utilization of genomics data produced by the

- 714 international *Pseudomonas aeruginosa* consortium. Front Microbiol 6:1036.
- 715 49. Nishida M, Mine Y, Matsubara T, Goto S, Kuwahara S. 1972. Bicyclomycin, a new  
716 antibiotic. III. In vitro and in vivo antimicrobial activity. J Antibiot 25:582–593.
- 717 50. Seipke RF, Song L, Bicz J, Laskaris P, Yaxley AM, Challis GL, Loria R. 2011. The plant  
718 pathogen *Streptomyces scabies* 87-22 has a functional pyochelin biosynthetic pathway  
719 that is regulated by TetR- and AfsR-family proteins. Microbiology 157:2681–2693.
- 720 51. Bown L, Li Y, Berru e F, Verhoeven JTP, Dufour SC, Bignell DRD. 2017. Coronafacoyl  
721 phytotoxin biosynthesis and evolution in the common scab pathogen *Streptomyces*  
722 *scabiei*. Appl Environ Microbiol 83:e01169-17.
- 723 52. Trippe K, McPhail K, Armstrong D, Azevedo M, Banowetz G. 2013. *Pseudomonas*  
724 *fluorescens* SBW25 produces furanomycin, a non-proteinogenic amino acid with selective  
725 antimicrobial properties. BMC Microbiol 13:111.
- 726 53. McDonald BR, Currie CR. 2017. Lateral Gene Transfer Dynamics in the Ancient Bacterial  
727 Genus *Streptomyces*. mBio 8:e00644-17.
- 728 54. Winstanley C, O’Brien S, Brockhurst MA. 2016. *Pseudomonas aeruginosa* evolutionary  
729 adaptation and diversification in cystic fibrosis chronic lung infections. Trends Microbiol  
730 24:327–337.
- 731 55. Quereda JJ, Dussurget O, Nahori M-A, Ghozlane A, Volant S, Dillies M-A, Regnault B,  
732 Kennedy S, Mondot S, Villoing B, Cossart P, Pizarro-Cerda J. 2016. Bacteriocin from  
733 epidemic *Listeria* strains alters the host intestinal microbiota to favor infection. Proc Natl

- 734 Acad Sci U S A 113:5706–5711.
- 735 56. Cardinale CJ, Washburn RS, Tadigotla VR, Brown LM, Gottesman ME, Nudler E. 2008.  
736 Termination factor Rho and its cofactors NusA and NusG silence foreign DNA in *E. coli*.  
737 Science 320:935–938.
- 738 57. Lindell D, Sullivan MB, Johnson ZI, Tolonen AC, Rohwer F, Chisholm SW. 2004. Transfer of  
739 photosynthesis genes to and from *Prochlorococcus* viruses. Proc Natl Acad Sci U S A  
740 101:11013–11018.
- 741 58. Arnold ML. 2006. Evolution through genetic exchange. Oxford University Press, Oxford.
- 742 59. Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA. 2000. Practical Streptomyces  
743 Genetics John Innes Foundation. John Innes Foundation, Norwich.
- 744 60. Miyamura S, Ogasawara N, Otsuka H, Niwayama S, Tanaka H, Take T, Uchiyama T, Ochiai  
745 H, Abe K, Koizumi K, Asao K, Matsuki K, Hoshino T. 1972. Antibiotic No. 5879, a new  
746 water-soluble antibiotic against Gram-negative bacteria. J Antibiot 25:610–612.
- 747 61. Watson M, Thomson M, Risse J, Talbot R, Santoyo-Lopez J, Gharbi K, Blaxter M. 2015.  
748 PoRe: An R package for the visualization and analysis of nanopore sequencing data.  
749 Bioinformatics 31:114–115.
- 750 62. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko  
751 SI, Pham S, Prjibelski AD, Pyshkin A V., Sirotkin A V., Vyahhi N, Tesler G, Alekseyev MA,  
752 Pevzner PA. 2012. SPAdes: A New Genome Assembly Algorithm and Its Applications to  
753 Single-Cell Sequencing. J Comput Biol 19:455–477.

- 754 63. Koren S, Walenz BP, Berlin K, Miller JR, Bergman NH, Phillippy AM. 2017. Canu: scalable  
755 and accurate long-read assembly via adaptive k-mer weighting and repeat separation.  
756 *Genome Res* 27:722–736.
- 757 64. Antipov D, Korobeynikov A, McLean JS, Pevzner PA. 2016. HybridSPAdes: An algorithm  
758 for hybrid assembly of short and long reads. *Bioinformatics* 32:1009–1015.
- 759 65. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics*  
760 30:2068–2069.
- 761 66. Hyatt D, Chen G-L, Locascio PF, Land ML, Larimer FW, Hauser LJ. 2010. Prodigal:  
762 prokaryotic gene recognition and translation initiation site identification. *BMC*  
763 *Bioinformatics* 11:119.
- 764 67. Sambrook J, Fritsch EF, Maniatis T. 1989. *Molecular Cloning: A Laboratory Manual*,  
765 Second Edition. Cold Spring Harbor Laboratory Press, New York.
- 766 68. Paget MS, Chamberlin L, Atrih A, Foster SJ, Buttner MJ. 1999. Evidence that the  
767 extracytoplasmic function sigma factor sigmaE is required for normal cell wall structure  
768 in *Streptomyces coelicolor* A3(2). *J Bacteriol* 181:204–211.
- 769 69. Medema MH, Takano E, Breitling R. 2013. Detecting sequence homology at the gene  
770 cluster level with MultiGeneBlast. *Mol Biol Evol* 30:1218–1223.
- 771 70. Diaz Caballero J, Clark ST, Coburn B, Zhang Y, Wang PW, Donaldson SL, Tullis DE, Yau  
772 YCW, Waters VJ, Hwang DM, Guttman DS. 2015. Selective Sweeps and Parallel  
773 Pathoadaptation Drive *Pseudomonas aeruginosa* Evolution in the Cystic Fibrosis Lung.

774 mBio 6:e00981-15.

775 71. Tange O. 2011. GNU Parallel - The Command-Line Power Tool. The USENIX Magazine  
776 36:42–47.

777 72. Miller MA, Pfeiffer W, Schwartz T. 2011. The CIPRES Science Gateway: A Community  
778 Resource for Phylogenetic Analyses, article 41. *In* Proceedings of the 2011 TeraGrid  
779 Conference: Extreme Digital Discovery. ACM, New York, NY, USA.

780 73. Boc A, Diallo AB, Makarenkov V. 2012. T-REX: a web server for inferring, validating and  
781 visualizing phylogenetic trees and networks. *Nucleic Acids Res* 40:W573–W579.

782 74. Letunic I, Bork P. 2016. Interactive tree of life (iTOL) v3: an online tool for the display and  
783 annotation of phylogenetic and other trees. *Nucleic Acids Res* 44:W242–W245.

784 75. Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high  
785 throughput. *Nucleic Acids Res* 32:1792–1797.

786 76. Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis  
787 of large phylogenies. *Bioinformatics* 30:1312–1313.

788 77. Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chitsaz F, Geer LY, Geer RC, He J,  
789 Gwadz M, Hurwitz DI, Lanczycki CJ, Lu F, Marchler GH, Song JS, Thanki N, Wang Z,  
790 Yamashita RA, Zhang D, Zheng C, Bryant SH. 2015. CDD: NCBI’s conserved domain  
791 database. *Nucleic Acids Res* 43:D222–D226.


792 78. Grant SG, Jessee J, Bloom FR, Hanahan D. 1990. Differential plasmid rescue from  
793 transgenic mouse DNAs into *Escherichia coli* methylation-restriction mutants. *Proc Natl*

794 Acad Sci U S A 87:4645–4649.

795 79. MacNeil DJ, Gewain KM, Ruby CL, Dezeny G, Gibbons PH, MacNeil T. 1992. Analysis of  
796 *Streptomyces avermitilis* genes required for avermectin biosynthesis utilizing a novel  
797 integration vector. Gene 111:61–68.

798 80. Rainey PB, Bailey MJ. 1996. Physical and genetic map of the *Pseudomonas fluorescens*  
799 SBW25 chromosome. Mol Microbiol 19:521–533.

800 FIGURES



801


802 **Figure 1.** Bicyclomycin biosynthesis. (A) Simplified schematic of BCM biosynthesis. (B) *bcm* gene

803 clusters identified in *S. cinnamoneus* and *P. aeruginosa*.


804

805






**Figure 2.** Heterologous expression of the *bcm* gene cluster from *S. cinnamoneus* in *S. coelicolor* M1146. Extracted ion chromatograms (EICs) of bicyclomycin ( $m/z$  285.11,  $[M-H_2O+H]^+$ ) in *S. cinnamoneus*, *S. coelicolor* M1146 expressing the *bcm* cluster and *S. coelicolor* M1146 containing empty vector. The intensity scale of each EIC is noted under the corresponding label.



**Figure 3.** Heterologous expression of the *bcm* cluster from *P. aeruginosa* in *P. fluorescens* SBW25. Base peak chromatograms of a bicyclomycin standard, *P. fluorescens* SBW25 expressing the *bcm* cluster and *P. fluorescens* SBW25 containing empty vector. The intensity scale of the chromatograms is noted under the corresponding labels. Compounds produced by the heterologous expression strain but not found in the control strain are highlighted in grey.



825 the phylogeny are shown at the base of each branch and the genetic context of each cluster  
826 (color-coded as in Fig. 1B) is shown for each branch of the tree. Flanking genes are color-coded  
827 grey if they encode proteins with conserved domains, white for hypothetical proteins with no  
828 conserved domains and red for proteins related to mobile genetic elements. Vertical black lines  
829 represent tRNAs. (C) Genetic context of the *bcm* clusters in Gram-negative bacteria. The black  
830 triangle represents a *attTn7* site.

831


832

833

834


835

836



837

838 **Figure 5.** Distribution of the *bcm* gene cluster across *P. aeruginosa* isolates using a modified  
839 version of the unrooted maximum-likelihood tree generated by Kos *et al.* (38). The PA14-like,  
840 PA7-like and PAO1-like clades are color-coded, and a green dot signifies the presence of the *bcm*  
841 gene cluster. *P. aeruginosa* SCV20265 and multiple reference strains (PAO1, M18, PA7, PA14) are  
842 also labelled.



843

844 **Figure 6.** Maximum likelihood tree of the *bcm* 2-OG dioxygenases, including all representatives  
 845 from *Streptomyces*, *Actinokineospora*, *Williamsia*, *Burkholderia* and *Tistrella*, two from  
 846 *Mycobacterium*, and eight from *Pseudomonas*. Protein BP3529 from *Bordetella pertussis* was  
 847 used as outgroup. Background colors and numbering of the branch labels represent the position  
 848 of a particular dioxygenase in the *bcm* gene cluster, as shown in the schematic representation.  
 849 The taxonomic origins of each protein are indicated by their branch and label colors (black for  
 850 Gram-positive and red for Gram-negative representatives). Bootstrap support values for the  
 851 major branches are shown. A reorganization of the *bcm* gene cluster between Gram-negative  
 852 and Gram-positive bacteria is proposed based on dioxygenase phylogeny.

853

854 TABLES

Strain or plasmid	Description	Reference
<b>Strains</b>		
<i>E. coli</i> DH5 $\alpha$	F <sup>-</sup> <i>endA1 glnV44 thi-1 recA1 relA1 gyrA96</i>	(78)
<i>E. coli</i> ET12567	<i>deoR nupG purB20 <math>\phi</math>80dlacZ<math>\Delta</math>M15 <math>\Delta</math>(lacZYA-argF)U169 hsdR17(<i>r<sub>K</sub><sup>-</sup>m<sub>K</sub><sup>+</sup></i>), <math>\lambda</math><sup>-</sup> F- <i>dam-13::Tn9 dcm-6 hsdM hsdR zjj-202::Tn10 recF143 galk2 galT22 ara-14 lacY1 xyl-5 leuB6 thi-1 tonA31 rpsL136 hisG4 tsx-78 mtl-1 glnV44</i></i>	(79)
<i>S. cinnamoneous</i> DSM 41675	Wild type producer of bicyclomycin	(1)
<i>S. coelicolor</i> M1146	$\Delta$ <i>act <math>\Delta</math>red <math>\Delta</math>cpk <math>\Delta</math>cda</i>	(31)
<i>S. coelicolor</i> M1152	$\Delta$ <i>act <math>\Delta</math>red <math>\Delta</math>cpk <math>\Delta</math>cda rpoB</i> [C1298T]	(31)
M1146-pIJ-BCM	M1146 containing pIJ-BCM	This study
M1152-pIJ-BCM	M1152 containing pIJ-BCM	This study
M1146-pIJ10257	M1146 containing pIJ10257	This study
M1152-pIJ10257	M1152 containing pIJ10257	This study
<i>P. aeruginosa</i> SCV20265	Clinical isolate from cystic fibrosis patient	(35, 36)
<i>P. fluorescens</i> SBW25	Environmental isolate	(80)
SBW25-pJH-BCMclp-PA	SBW25 containing pJH-BCMclp-PA	This study
SBW25-pJH10TS	SBW25 containing pJH10TS	This study
<b>Plasmids</b>		
pIJ10257	<i>Streptomyces</i> $\phi$ BT1 integrative vector, Hyg <sup>R</sup> , <i>ermE</i> *p	(28)
pIJ-BCM	pIJ10257 containing <i>bcm</i> cluster from <i>Streptomyces</i>	This study
pUZ8002	Helper plasmid for intergeneric conjugation, Kan <sup>R</sup>	(68)
pJH10TS	<i>Pseudomonas</i> expression vector, Tc <sup>R</sup> , tac promoter	(40)
pJH-BCMclp-PA	pJH10TS containing <i>bcm</i> cluster from <i>P. aeruginosa</i>	This study

855

856 **Table 1.** Strains and plasmids used or generated in this study.

Primer name	Sequence 5'→3'	Use
pIJ-bcm_start	GGTAGGATCGTCTAGAACAGGAGGCC <u>CATATGT</u> CGCTAGAAGCGCAGCTGATGGAGCCT	Amplification and assembly of
pIJ-bcm_end	CCAAGCTTATGCAGGACTCTAG <u>TAAATTA</u> AACCG GAACTGAGCGGATCCCCGTGGCTGA	<i>Streptomyces bcm</i> cluster in pIJ10257
bcm-cdps_chk_fw	CTGATGGAGCCTCGGGAAGAACC	PCR verification of exconjugants
bcm-cdps_chk_rv	GCAGGCGCTCGTGGTAGTCG	
BCM_seq_1	TCCACCTGAAAGGGCGATGAC	pIJ-BCM sequencing verification
BCM_seq_2	TCGTCATCAACTTCGGTCTGTCTG	
BCM_seq_3	CTTCGTGACCGTCCTCTACATCG	
BCM_seq_4	GGTGGACAGCCTCGTGCCC	
BCM_seq_5	CCTGAGTCTGAAGAGGCACGC	
BCM_seq_6	GTCTCCACGGAACGGGCG	
BCM_seq_7	CGGCTACGAGATCCTCCACGA	
BCM_seq_8	CACAAGGACTCCGGCTGGG	
pJH-BCMclp_start	TAACTGCGCTAGCACCTCTCGAGGCAT <u>CATATG</u> GC CAAACCCAGATCGACG	Amplification and assembly of
pJH-BCMcl_end	AGGCGGTACGCTCTCCAGCGAGCT <u>TCTAGA</u> AGC CGGGGCAGGCATGC	<i>Pseudomonas bcm</i> cluster in pJH10TS
pJH_chk_fw	TAATGTGTGGAATTGTGAGCGG	PCR verification of transformants
pJH_chk_rv	TGAGCCAAATGAGGCGGTC	
BCM_PA_seq_1	GCGTAACTATTCCTGGAGCACT	pJH-BCMclp-PA sequencing verification
BCM_PA_seq_2	TAACCTTCAATCACTATCGCCC	
BCM_PA_seq_3	GAACGGATGCACGAGATCGC	
BCM_PA_seq_4	TCTGGCTCGGAGACGACCTG	
BCM_PA_seq_5	GTAGTAGACAACCCGGAACAAGC	
BCM_PA_seq_6	CACAGGTGCCGACCAGGAC	
BCM_PA_seq_7	TCTTCGATCATCCAGACGGC	
BCM_PA_seq_8	CAACGACGACATCCTCCTCTG	
BCM_PA_seq_9	ATGCCCTGTTCGTGGATAGC	

857

858 **Table 2.** Primers used in this study. Restriction sites used for assembly are underlined and in

859 bold type.